Bristol-Myers Squibb Enter Partnership with Tibotec Pharmaceuticals

Bristol-Myers Squibb have entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies, to assess the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, combined with Tibotec Pharmaceuticals’ investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV). Within the agreement, the two

Continue Reading

EU Approval for Komboglyze and Onglyza

AstraZeneca and Bristol-Myers Squibb are celebrating after European regulators approved two of their diabetes drugs. AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for Komboglyze, which combines the DPP-4 inhibitor Onglyza (saxagliptin) with metformin in a once-a-day tablet. The combination is to be used as an adjunct to

Continue Reading

Disappointment as NICE Rejects Skin Cancer Drug

The conclusion by the UK’s National Institute for Health and Clinical Excellence (NICE) to reject Bristol-Myers Squibb’s new melanoma drug Yervoy has been greeted with disappointment by the company and patient groups. In a provisional draft guidance published earlier today, NICE decided against recommending payment by the UK’s National Health Service (NHS) of Yervoy (ipilimumab)

Continue Reading

BMS Foundation Announces Collaboration with WHO Stop TB Department

The Bristol-Myers Squibb Foundation yesterday announced a partnership with the World Health Organization’s (WHO) Stop TB Department for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis (TB) including co-infection with HIV in South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo. These countries represented more than 13%

Continue Reading

Bristol-Myers Squibb Completes Amira Pharmaceuticals Acquisition

Bristol-Myers Squibb (BMS) Company has completed its previously announced acquisition of  Amira Pharmaceuticals, a privately held small-molecule pharmaceutical company, focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  As a result of the transaction, Amira Pharmaceuticals has now become a wholly-owned subsidiary of Bristol-Myers Squibb. The acquisition of

Continue Reading

NICE Rejects BMS’ Orencia For RA

NICE (the National Institute for Health and Clinical Excellence) has issued final guidance rejecting the use of Bristol-Myers Squibb’s Orencia (abatacept) as a second-line treatment for rheumatoid arthritis (RA). The guidance says that the use of Orencia is not recommended in combination with methotrexate for treating RA in adults whose disease has responded inadequately to

Continue Reading

GNS Announces Collaboration with BMS

GNS Healthcare have announced a collaboration with Bristol-Myers Squibb (BMS) to provide a computer model that can support virtual clinical trials in the field of immuno-inflammation. No financial terms were disclosed on the tie-up, under which GNS will take clinical and molecular information from a BMS clinical trial and will use its supercomputer-driven REFS (reverse-engineering

Continue Reading

Bristol-Myers Squibb to acquire Amira

Bristol-Myers Squibb has hit the acquisition trail again and is buying privately held Amira Pharmaceuticals in a deal that could be worth $475 million to the inflammatory and fibrotic diseases specialist. Under the terms of the agreement, B-MS is shelling out $325 million in an upfront fee and may make additional milestone payments totalling $150

Continue Reading